leisure time -WSS

leisure time

author：entertainment 2025-09-07 21:51:45 - browse：75522

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

WSS

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

WHO calls for emergency meeting on new China virus, as cases spread

Hospitals consider fixing cancer drug shortages on their own

WATCH: Why do bright lights make us see spots?

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Private equity could exacerbate cardiology's overuse problem, experts fear

explore

leisure time

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Sanders adds drug shortage policies to pandemic preparedness bill

23andMe had bad news about my health. I wish a person had delivered it

Long Covid needs a new name — and a new frame

BioMarin wins approval for gene therapy to treat hemophilia A

Long Covid needs a new name — and a new frame

Wildfire smoke exposes gaps in outdoor worker protections

Will the IRA bring competition to the biologics market?

Supreme Court strikes down use of affirmative action

Food makers to regulators: Ultra

hotspot

How Medicaid coverage policies for immigrants impact new moms

WHO calls for emergency meeting on new China virus, as cases spread

How medical schools plan to diversify without affirmative action

Food makers tried to stack nutrition panel with preferred experts

How to make the FDA’s new prescription one

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

focus

focus

knowledge

focus